Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
<h4>Aim</h4>Several pathophysiological processes are involved in Parkinson's disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer's Disease, in a PD cohort.<h4>Methods</h4>Longitudinal cerebrospinal flu...
Main Authors: | Michael Bartl, Mohammed Dakna, Douglas Galasko, Samantha J Hutten, Tatiana Foroud, Marian Quan, Kenneth Marek, Andrew Siderowf, Jonas Franz, Claudia Trenkwalder, Brit Mollenhauer, Parkinson’s Progression Markers Initiative |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0257372 |
Similar Items
-
Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study.
by: Yu Zhang, et al.
Published: (2016-01-01) -
Cross-sectional proteomic expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with longitudinal clinical follow-up
by: Ilham Yahya Abdi, et al.
Published: (2023-02-01) -
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
by: Kalpana M. Merchant, et al.
Published: (2023-02-01) -
Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease
by: Michael Bartl, et al.
Published: (2022-08-01) -
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
by: Tanya Simuni, et al.
Published: (2022-10-01)